| Takeda2 programs in shared conditions | 2Multiple Myeloma, Myelodysplastic Syndromes | Immunoglobulins, Intravenous, elritercept | - Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan vs levoleucovorin calcium (most trials: Takeda) (Biliary Tract Neoplasms, NCT07606599)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s izalontamab brengitecan vs levoleucovorin calcium (most trials: Takeda) (Biliary Tract Neoplasms, NCT07582315)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan vs fruquintinib (US & EU rights: Takeda) (Colorectal Neoplasms, NCT07730489)
|
| Hoffmann-La Roche18 programs in shared conditions | 9 · 2 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Large B-Cell, Diffuse +6 | inavolisib, giredestrant, bizrolertinib +3 | - Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan vs Ado-Trastuzumab Emtansine (US & EU rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06316531)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan vs Ado-Trastuzumab Emtansine (US & EU rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06830889)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan added to pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT06891833)
- and 2 more
|
| BeOne Medicines9 programs in shared conditions | 6 · 2 with both in phase 3Breast Neoplasms, Carcinoma, Ovarian Epithelial, Carcinoma, Hepatocellular +3 | CDK4 Inhibitor BGB-43395, Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033, Anti-B7-H4 Antibody Drug Conjugate BG-C9074 | - Sichuan Biokin Pharmaceutical Co., Ltd.’s izalontamab brengitecan in a combination vs tislelizumab (US & EU rights: BeOne Medicines) (Carcinoma, Non-Small-Cell Lung, NCT07739186)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s PD-1/VEGF Bispecific Antibody in a combination vs tislelizumab (US & EU rights: BeOne Medicines) (Carcinoma, Non-Small-Cell Lung, NCT07739186)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s izalontamab brengitecan added to tislelizumab (US & EU rights: BeOne Medicines) (Esophageal Squamous Cell Carcinoma, NCT07554456)
- and 1 more
|
| Bristol-Myers Squibb20 programs in shared conditions | 10 · 4 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Prostatic Neoplasms +7 | Nivolumab, adagrasib, pumitamig +6 | - Sichuan Biokin Pharmaceutical Co., Ltd.’s izalontamab brengitecan vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Breast Neoplasms, NCT07648914)
- Sichuan Biokin Pharmaceutical Co., Ltd.’s izalontamab brengitecan in a combination vs Albumin-Bound Paclitaxel (EU rights: Bristol-Myers Squibb) (Triple Negative Breast Neoplasms, NCT07729956)
|
| Merck & Co., Inc16 programs in shared conditions | 13 · 6 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms +10 | sacituzumab tirumotecan, patritumab deruxtecan, intismeran autogene +6 | - Sichuan Biokin Pharmaceutical Co., Ltd.’s trastuzumab brengitecan vs pembrolizumab (US & EU rights: Merck & Co., Inc) (Carcinoma, Non-Small-Cell Lung, NCT07178795)
|